In the cancer-immunity cycle, HDAC inhibition enhances antigen presentation by increasing major histocompatibility complex (MHC) class I and II in Merkel cell carcinoma [12], bladder cancer [13], and NSCLC [14], resulting in the promotion of cytotoxic CD8+ T-cell-mediated tumor cell killing. The gene discussed is HDAC9; the disease is non-small cell lung carcinoma.